News NHS cleared to use Astellas' non-hormonal menopause drug Around half a million women will soon be able to access Astellas' Veoza treatment for symptoms like hot flushes associated with menopause.
Market Access Women's health: Predictions for 2026 A forward glance at new funding vehicles, national strategies, and innovative solutions reshaping the underlying infrastructure of women's care.
News Bayer gets EU approval for menopause drug Lynkuet Bayer now has approval on both sides of the Atlantic for Lynkuet, with the EU backing it for symptoms caused by both menopause and breast cancer.
News Poll paints picture of menopause discrimination at work A survey of women across six countries has found more than a third have experienced some kind of negative impact in the workplace due to menopause.
News Gedeon Richter brings HRT option back to the UK market After a 17-year absence, a dydrogesterone-only hormone replacement therapy (HRT) formulation is available again in the UK market.
News Astellas pays $285m for Audax cancer drug, and other deals Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
